Match!

A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells

Published on May 15, 2017in Journal of Virology4.324
路 DOI :10.1128/JVI.00067-17
Valerio Leoni8
Estimated H-index: 8
(UNIBO: University of Bologna),
Valentina Gatta4
Estimated H-index: 4
(UNIBO: University of Bologna)
+ 3 AuthorsGabriella Campadelli-Fiume41
Estimated H-index: 41
(UNIBO: University of Bologna)
Abstract
  • References (38)
  • Citations (7)
馃摉 Papers frequently viewed together
5 Citations
20 Citations
11 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References38
Newest
#1Antonio Marchini (DKFZ: German Cancer Research Center)H-Index: 18
#2Eleanor M. Scott (DKFZ: German Cancer Research Center)H-Index: 5
Last. Jean RommelaereH-Index: 43
view all 3 authors...
Oncolytic viruses (OVs) target and destroy cancer cells while sparing their normal counterparts. These viruses have been evaluated in numerous studies at both pre-clinical and clinical levels and the recent Food and Drug Administration (FDA) approval of an oncolytic herpesvirus-based treatment raises optimism that OVs will become a therapeutic option for cancer patients. However, to improve clinical outcome, there is a need to increase OV efficacy. In addition to killing cancer cells directly th...
32 CitationsSource
US regulators clear a viral melanoma therapy, paving the way for a promising field with a chequered past.
55 CitationsSource
#1Valerio LeoniH-Index: 8
#2Valentina Gatta (UNIBO: University of Bologna)H-Index: 28
Last. Gabriella Campadelli-Fiume (UNIBO: University of Bologna)H-Index: 41
view all 13 authors...
// Valerio Leoni 1,* , Valentina Gatta 1,* , Arianna Palladini 1 , Giordano Nicoletti 1 , Dario Ranieri 1 , Massimiliano Dall鈥橭ra 1 , Valentina Grosso 1 , Martina Rossi 1 , Francesco Alviano 1 , Laura Bonsi 1 , Patrizia Nanni 1 , Pier-Luigi Lollini 1 and Gabriella Campadelli-Fiume 1 1 Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy * These authors have contributed equally to this work Correspondence to: Gabriella Campadelli-Fiume, email: // Pi...
25 CitationsSource
#1Robert H.I. Andtbacka (UofU: University of Utah)H-Index: 28
#2Howard L. Kaufman (RU: Rutgers University)H-Index: 49
Last. R. S. Coffin (Amgen)H-Index: 10
view all 29 authors...
Purpose Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1鈥恉erived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic antitumor immune responses. T-VEC was compared with GM-CSF in patients with unresected stage IIIB to IV melanoma in a randomized open-label phase III trial. Patients and Methods Patients with injectable melanoma that was not surgically resectable were rand...
775 CitationsSource
Viruses have been suggested to be useful as anti-cancer agents since the early 20th century, although following the advent of chemotherapy and radiotherapy work largely stopped until the 1990s when a number of groups began to explore the use of engineered viruses. This overview summarizes the development of the field from the 1990s to the present day, an era when oncolytic viruses have now demonstrated clear clinical benefit to patients. The hurdles and challenges which needed to be overcome are...
32 CitationsSource
#1Valentina Gatta (UNIBO: University of Bologna)H-Index: 4
#2Biljana Petrovic (UNIBO: University of Bologna)H-Index: 5
Last. Gabriella Campadelli-Fiume (UNIBO: University of Bologna)H-Index: 41
view all 3 authors...
20 CitationsSource
#1Christine E. Engeland (DKFZ: German Cancer Research Center)H-Index: 9
#2Christian Grossardt (DKFZ: German Cancer Research Center)H-Index: 8
Last. Guy Ungerechts (DKFZ: German Cancer Research Center)H-Index: 17
view all 13 authors...
We hypothesized that the combination of oncolytic virotherapy with immune checkpoint modulators would reduce tumor burden by direct cell lysis and stimulate antitumor immunity. In this study, we have generated attenuated Measles virus (MV) vectors encoding antibodies against CTLA-4 and PD-L1 (MV-aCTLA-4 and MV-aPD-L1). We characterized the vectors in terms of growth kinetics, antibody expression, and cytotoxicity in vitro. Immunotherapeutic effects were assessed in a newly established, fully imm...
128 CitationsSource
Oncolytic viruses can infect and destroy tumour tissues; however, many have proven less effective in clinical trials than anticipated. Miest and Cattaneo outline strategies to enhance the efficacy of next-generation virotherapy and to provide the clinic with a range of viruses that are engineered to safely and specifically destroy cancer cells.
143 CitationsSource
#1Hiroaki Uchida (Tokyo University of Pharmacy and Life Sciences)H-Index: 15
#2Marco Marzulli (University of Pittsburgh)H-Index: 4
Last. Joseph C. Glorioso (University of Pittsburgh)H-Index: 63
view all 19 authors...
Glioblastoma multiforme (GBM) remains an untreatable human brain malignancy. Despite promising preclinical studies using oncolytic herpes simplex virus (oHSV) vectors, efficacy in patients has been limited by inefficient virus replication in tumor cells. This disappointing outcome can be attributed in part to attenuating mutations engineered into these viruses to prevent replication in normal cells. Alternatively, retargeting of fully replication-competent HSV to tumor-associated receptors has t...
47 CitationsSource
#1Patrizia Nanni (UNIBO: University of Bologna)H-Index: 45
#2Valentina Gatta (UNIBO: University of Bologna)H-Index: 28
Last. Pier Luigi Lollini (UNIBO: University of Bologna)H-Index: 53
view all 14 authors...
Oncolytic viruses aim to specifically kill tumor cells. A major challenge is the effective targeting of disseminated tumors in vivo. We retargeted herpes simplex virus (HSV) tropism to HER-2 oncoprotein p185, overexpressed in ovary and breast cancers. The HER-2-retargeted R-LM249 exclusively infects and kills tumor cells expressing high levels of human HER-2. Here, we assessed the efficacy of systemically i.p. delivered R-LM249 against disseminated tumors in mouse models that recapitulate tumor ...
22 CitationsSource
Cited By7
Newest
#1Laura Menotti (UNIBO: University of Bologna)H-Index: 17
#2Elisa Avitabile (UNIBO: University of Bologna)H-Index: 21
Last. Gabriella Campadelli-Fiume (UNIBO: University of Bologna)H-Index: 41
view all 6 authors...
Previously, we engineered oncolytic herpes simplex viruses (o-HSVs) retargeted to the HER2 (epidermal growth factor receptor 2) tumor cell specific receptor by the insertion of a single chain antibody (scFv) to HER2 in gD, gH, or gB. Here, the insertion of scFvs to three additional cancer targets鈥擡GFR (epidermal growth factor receptor), EGFRvIII, and PSMA (prostate specific membrane antigen)鈥攊n gD 螖6鈥38 enabled the generation of specifically retargeted o-HSVs. Viable recombinants resulted from t...
5 CitationsSource
#1Paul J. F. Rider (LSU: Louisiana State University)H-Index: 4
#2Farhana Musarrat (LSU: Louisiana State University)H-Index: 2
Last. Konstantin G. Kousoulas (LSU: Louisiana State University)H-Index: 26
view all 5 authors...
Purpose of Review The earliest host-virus interactions occur during virus attachment and entry into cells. These initial steps in the virus lifecycle influence the outcome of infection beyond delivery of the viral genome into the cell. Herpesviruses alter host signaling pathways and processes during attachment and entry to facilitate virus infection and modulate innate immune responses. We suggest in this review that understanding these early events may inform the rational design of therapeutic ...
1 CitationsSource
#1Xiao-Qin Liu (Yangtze University)H-Index: 1
#2Hong-Yi XinH-Index: 1
Last. Hong-Wu Xin (Yangtze University)H-Index: 1
view all 14 authors...
Oncolytic herpes simplex viruses (oHSVs) have been approved for clinical usage and become more and more popular for tumor virotherapy. However, there are still many issues for the oHSVs used in clinics and clinical trials. The main issues are the limited anti-tumor effects, intratumor injection, and some side effects. To overcome such challenges, here we review the genetic engineering of the envelope glycoproteins for oHSVs to target tumors specifically, and at the same time we summarize the man...
Source
#1Valerio Leoni (UNIBO: University of Bologna)H-Index: 8
#2Biljana Petrovic (UNIBO: University of Bologna)H-Index: 5
Last. Gabriella Campadelli-Fiume (UNIBO: University of Bologna)H-Index: 41
view all 5 authors...
1 CitationsSource
#1Biljana PetrovicH-Index: 5
#2Valerio LeoniH-Index: 8
view all 6 authors...
3 CitationsSource